Born in Milan in 1955, Sergio Dompé is an entrepreneur in the pharmaceutical and biotechnological industries and President of Dompé, a pharmaceutical group developing innovative therapeutic solutions for rare and orphan diseases.

He has been awarded honorary doctorates in Biotechnology with specialization in pharmaceutics (Bologna, 1996), Medical Biotechnology (L’Aquila, 2005) and Pharmacy (Urbino, 2010).

Among the first in Italy to grasp the true value of biotechnology applied to human health, he has developed an extensive network of partnerships with the most significant research centres for diseases in Dompé’s main therapeutic fields.

In 2016, he funded and established Movendo, an innovative medical company sparkled by an idea by the Italian Institute of Technology: to develop the most advanced technologies at the service of mankind and products in the field of physical movement rehabilitation.

In 2004 he was awarded the “La Lombardia per il lavoro” prize, in recognition of his value as one of Lombardy’s most innovative entrepreneurs.

In 2016, he received the Prize of the Foundation Aiuto per la Ricerca sulle Malattie Rare (A.R.M.R.), regularly awarded to those who distinguish themselves in the research field.

In 2017 he was awarded the Guido Carli prize.

Institutional offices held

• From 1998 to 2004: President of Assobiotec

• Since 2004, anchor investor in Philogen, a leader in the research and development of antibodies

• From 2005 to 2011: President of Farmindustria

• From 2006 to 2011: Chairman of the Evaluation Committee of the CNR (Consiglio Nazionale delle Ricerche, National Research Council).

• From 2007 to 2015: member of the Board of the IIT (Italian Institute of Technology) Foundation

• From 2014 to 2016: member of the Patent Experts Committee of the CNR

• From 2014 to 2016: member of the Board of Regency of the Bank of Italy (Milan office)

• Since 2015: member of the General Council of Confindustria as representative of Farmindustria

• Since 2016: Censor of the Bank of Italy (Milan office)

• Since 2019: Vice President of Assolombarda with delegated powers over Life Sciences

• 2020: Chairman of the 2021 B20 Life Sciences task-force.

Nathalie Dompé is Co-CEO of Dompé farmaceutici and Vice President of Business Development of the Dompé group. Nathalie is responsible for the oversight, market development, and strategic approval of all new drugs launched by Dompé in the United States. She explores new opportunities for the company through interactions with other business leaders in the pharmaceutical and high tech industries.

Nathalie is concurrently CEO, of Dompé Holdings, a diversified holding company in Europe with business interests in pharmaceuticals, agriculture, and hi-tech. She sits on the board of several companies including Movendo, Philogen and Dompé farmaceutici. Nathalie graduated with Honors in Business Administration from Bocconi University in Milan. In her free time Nathalie enjoys spending time with her family in the Bay Area, and abroad.

After graduating in Economics at "La Sapienza" University in Rome, she completed her studies with an MBA at Politecnico di Milano.

In 2005 she joined Bain & Company where she gained a consolidated and internationally recognized expertise in the healthcare sector.

She joined Dompé in 2018 as Chief Operating Officer (COO) and she’s in charge of leading the company's internationalization project, with an emphasis on biotechnology, following the FDA approval of the first therapy for neurotrophic keratitis.

The COO coordinates the company’s activities, with the strategic goal of providing patients with highly innovative solutions in response to unmet medical needs.

With a degree in Medical Chemistry from The Sapienza University of Rome, Marcello is a member of the American Chemical Society since 1988 and the Italian Chemistry Society since 2006.

After a brief period as a university researcher, he joined Dompé as a team leader, followed by a period as Research Director and, since 2009, as a Chief Scientific Officer.

He leads Dompe’s Research and Development activities and pre-clinical and clinical drug development programs - from active ingredient identification to market authorization - including relationships with international regulatory authorities.

Marcello also holds a number of university teaching positions and maintains his scientific interests, with published work in over forty scientific journals. He is Associate Editor for several journals.

He has also filed over thirty international patents.

Giuseppe Andreano joined Dompé in 2007.

Following a degree in Business Administration from Bocconi University in Milan, Giuseppe gained experience in administration and financial management with major multinational companies.

Giuseppe is Dompe’s Chief Financial Officer in charge of administration, budgets and financial control. He also manages IT and purchases.

Andrea has over 20 years of experience in the Human Resources, Legal & Compliance Departments of commercial and industrial organizations in the pharma sector. Graduated in Law from the Università Statale di Milano and from Insead Business School’s Leadership Development Program, he is a lawyer articled clerk and has worked extensively in multinational pharmaceutical groups with an excellent track record ranging from HR to compliance.

Graduated in Biological Science at La Sapienza University in Rome, after a brief period as researcher, Stefano started his career in the pharmaceutical and consumer health business, working for both national and multinational companies, across multiple sites and geographical regions. Coming from Alfasigma, where, as Corporate Quality and Operations, he has played a key role in the post-merger integration process.

He also worked for Catalent Pharma solutions, a leading provider in the CDMO business, firstly as VP Quality Europe, Japan and Australia and later assuming the role of General Manager of the Italian subsidiary. Stefano joined Dompé in 2020 as Head of Quality Corporate VP, being accountable for strengthening quality governance model and continuously improving company quality standards.

From 2021 as Chief Industrial Officer, he is in charge of leading the industrial team, supporting the company’s strategic growth, while improving overall manufacturing network efficiency.

Ashley joined Dompé in 2018 to build the US organization. Prior to joining Dompé, Ashley led the Commercial Strategy & Pharmaceutical Development function at Santen, Inc, and previously was responsible for corporate and commercial planning at Adverum Biotechnologies.

Before that she worked on the Retina Franchise at Genentech. Earlier in her career she worked in the Chicago and San Francisco offices of Bain & Company.

She earned her MBA from the Kellogg School of Management at Northwestern University and her BA with Distinction from the University of North Carolina at Chapel Hill.

Ashley spends her free time on the soccer sidelines, helping with math homework, and putting the green thumb she inherited from her grandmother to work in her gardens.

Graduated in Medicine and Surgery summa cum laude, Flavio completed his specialization program in ophthalmology and a Ph.D. at the Campus Bio-Medico University of Rome. He also completed a postdoctoral fellowship in ocular surface glycobiology at the Schepens Eye Research Institute - Harvard Medical School in Boston.

Prior to joining Dompé, Flavio researched the application of neurotrophins in ophthalmic and neurodegenerative diseases and was an adjunct associate professor of biology at Temple University in Philadelphia.

His professional experience includes positions at the IRCCS G.B. Bietti Hospital in Rome as a clinical scientist and as a consultant ophthalmologist at the Campus Biomedico University of Rome and the Cornea and Ocular Surface Unit of the Vita-Salute San Raffaele University of Milan.

Flavio joined Dompé in 2014, and has been instrumental in developing Oxervate into a revolutionary product for a rare and potentially blinding orphan corneal disease, neurotrophic keratitis. In 2019 he was appointed Chief Medical Officer.

As Chief Medical Officer and Head of R&D for the Ophthalmology and Neurotrophin platforms, Flavio leads all clinical research and development programs in ophthalmology with particular attention to the applications of NGF in ophthalmic diseases and other therapeutic areas.

He is the author of numerous scientific publications in international journals.

Davide graduated in Business Administration from Bocconi University in Milan. Since 2015, he has been managing Dompé’s Commercial Operations in Primary Care at national and international level.

Before taking on this role, he held a number of different marketing and sales positions within the company, focusing on the promotion and development of OTC and ethical drugs.

Daniele holds a degree in Business Administration from Bocconi University in Milan. He has worked for over 30 years in the ICT transformation and digitization of various companies and industries.

He began his professional career as a consultant in a leading consulting firm, then as a project and IT manager in a regional group of supermarkets.

He joined Autogrill in 1999 as ICT project manager responsible for the European branches, and then held the role of CIO for Italy and Europe for over 10 years, carrying out various and recognized digital innovation projects.

He contributed to the creation of the ICT & Admin shared service center and its transformation into a separate legal entity (AABS spa) which he led as General Manager until 2019.

Together with G. Bongiorno and G. Vaia he has published the book “CIOs and the digital transformation. A new leadership role "(Springer 2018)

With more than 20 years of experience in the biotechnology industry, Caryn holds deep expertise in legal, compliance, and business leadership. She oversees the global legal and compliance functions for Dompé. Prior to joining Dompé, Caryn served as Chief Legal and Administrative Officer of Quince Therapeutics where she drove legal strategy, compliance, government affairs, and corporate governance. Previously, she served as Senior Vice President, General Counsel at Revance Therapeutics and General Counsel and Chief Compliance Officer at Cytokinetics. Earlier in her life sciences career, Caryn served in roles of increasing responsibility at Millennium Pharmaceuticals, Genentech, Affymax, Onyx Pharmaceuticals, and InterMune.

Prior to industry, Caryn served as a state and federal prosecutor at the Attorney General’s Office of the Commonwealth of Massachusetts and the Office of the Inspector General of the Department of Health and Human Services.

Caryn holds a J.D. from the Boston University School of Law and her B.A. from the University of Michigan. Caryn serves as a board member of California Life Sciences, a non-profit biotech association.